文献速递脑血管病神经重症与神经感染

大核心脑梗死后重症决策:SELECT2试验二次分析

Critical Care Decisions After Large Core Cerebral Infarctions: A Secondary Analysis From the SELECT2 Trial.
PubMed 文献 · Ann Neurol · 2024-12-09

本研究分析SELECT2试验352例大血管闭塞伴大核心梗死患者,比较血管内取栓与药物治疗后去骨瓣减压术和早期撤除生命支持治疗的使用情况。取栓组与药物组接受去骨瓣减压术(16% vs 15%)或早期撤除生命支持治疗(22% vs 24%)的可能性无显著差异,去骨瓣减压术更多用于年轻患者,早期撤除生命支持治疗更多用于老年患者。

要点

  • 取栓组与药物组去骨瓣减压术使用率无显著差异(16% vs 15%,aRR=1.19,95%CI 0.75-1.88,P=0.46)
  • 取栓组与药物组早期撤除生命支持治疗率无显著差异(22% vs 24%,aRR=0.94,95%CI 0.66-1.34,P=0.72)
  • 去骨瓣减压术后1年21%患者可独立行走,早期撤除生命支持治疗后结局普遍不良

核心结论

  • 在大核心梗死患者中,约六分之一接受去骨瓣减压术,约五分之一接受早期撤除生命支持治疗,两者均不因取栓或药物治疗而不同,也不因成功再灌注而不同。
  • 去骨瓣减压术或早期撤除生命支持治疗并未削弱取栓的治疗获益。
  • 尽管接受去骨瓣减压术,约20%患者在1年随访时仍实现独立行走。
  • 这些重症决策的分布相似,提示总体试验结局未因开放标签治疗分配而偏倚。

研究设计与样本

  • SELECT2试验的二次分析,纳入352例因大血管闭塞伴大核心梗死而随机分配至血管内取栓或药物治疗的患者。
  • 采用按治疗实际分析原则,比较随机化后7天内去骨瓣减压术和早期撤除生命支持治疗的使用情况。
  • 进一步评估这些决策后的功能结局(改良Rankin量表)。

主要发现

  • 352例患者中,55例接受去骨瓣减压术,81例转为早期撤除生命支持治疗。
  • 取栓组与药物组接受去骨瓣减压术的比例分别为16%和15%(aRR=1.19,95%CI 0.75-1.88,P=0.46)。
  • 取栓组与药物组接受早期撤除生命支持治疗的比例分别为22%和24%(aRR=0.94,95%CI 0.66-1.34,P=0.72)。
  • 去骨瓣减压术更多用于年轻患者,早期撤除生命支持治疗更多用于老年患者。
  • 调整去骨瓣减压术后取栓疗效仍维持(aGenOR=1.68,95%CI 1.24-2.11,P<0.001),去骨瓣减压术与治疗之间无交互作用(P交互=0.93)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Among patients with large vessel occlusion (LVO) and large ischemic cores, critical decisions often need to be made about decompressive hemicraniectomy (DHC) or early withdrawal of life-sustaining therapy (WLST). In this study, we aimed to evaluate utilization of DHC and early WLST and factors associated with them in patients with large strokes from the SELECT2 trial. METHODS: We analyzed the entire SELECT2 trial population, which randomized 352 patients with stroke due to LVO and large ischemic cores to endovascular thrombectomy (EVT) or medical management. We used the as-treated principle to compare the use of DHC and early WLST within 7 days after randomization. We further assessed functional outcomes (modified Rankin Score) after these decisions. RESULTS: Of 352 patients enrolled in this study, 55 received DHC and 81 transitioned to early WLST. Patients treated with EVT were as likely to undergo DHC (16% vs 15%, adjusted relative risk [aRR] = 1.19, 95% CI:0.75-1.88, p = 0.46) or WLST (22% vs 24%, aRR = 0.94, 95% CI: 0.66-1.34, p = 0.72) as those given medical management. DHC was used more frequently in younger patients and WLST more in older patients. EVT efficacy was maintained after adjusting for DHC (adjusted generalized odds ratio [aGenOR] = 1.68, 95% CI: 1.24-2.11, p < 0.001), with no interaction between DHC and treatment (p-interaction = 0.93). At 1 year, 21% of DHC-treated patients were ambulatory; the outcomes were universally poor after early WLST. INTERPRETATION: In the SELECT2 trial of patients with large ischemic core, DHC was performed in ~1 of 6 patients and early WLST in ~1 of 5 patients, without differences based on treatment with EVT or medical management, nor successful reperfusion. DHC or WLST did not detract from thrombectomy treatment benefit. Additionally, ~20% of patients achieved independent ambulation despite receiving DHC by the 1-year follow-up. The similar distribution of these critical care decisions provides reassurance that the overall trial outcomes were not biased by open-label treatment allocation. ANN NEUROL 2025;97:698-708.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Kasner SE, Mullen MT, DeGeorgia M, et al. Critical Care Decisions After Large Core Cerebral Infarctions: A Secondary Analysis From the SELECT2 Trial. Ann Neurol. 2024. PMID: 39648975. doi:10.1002/ana.27151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。